BridgeBio Pharma Inc
BridgeBio Pharma Inc (BBIO) Unusual Options Activity Today
BBIO's highest volume power reading is 28.57%, on the $70 PUT expiring Dec 18, 2026. This strike traded 2 contracts against just 7 in open interest. On the call side, the highest reading is the $95 CALL expiring Dec 18, 2026 at 100.00%, with 5 contracts traded against 5 open, as of Nov 20, 2026.
Read more
Checking BBIO unusual options activity helps you spot when traders are making outsized bets on BridgeBio Pharma Inc before the broader market catches on. Unusual activity flags contracts trading at multiples of their average daily volume, often signaling informed money positioning ahead of a catalyst. Use our scanner to monitor BBIO unusual options activity today and surface the prints that deserve a second look.
Unusual options flow typically means volume vastly exceeds open interest at a given strike, or total contract volume on a name spikes well above its norm. Watching BBIO unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking BBIO unusual options volume across calls and puts helps you separate hedging from genuinely speculative positioning, especially valuable around earnings, product launches, and macro events.
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.
| 95.00 | — | 0.50 | 0.50 | 57% | 5 | 5 | 100.00% |
| 77.50 | 2.45 | 4.30 | 3.38 | 47% | 17 | 30 | 56.67% |
| 82.50 | 0.90 | 3.60 | 2.25 | 54% | 22 | 72 | 30.56% |
| 60.00 | 14.60 | 18.50 | 16.55 | 59% | 3 | 22 | 13.64% |
| 90.00 | 0.20 | 1.00 | 0.60 | 49% | 6 | 47 | 12.77% |
| 70.00 | 1.00 | 2.70 | 1.85 | 53% | 2 | 7 | 28.57% |
| 80.00 | 5.30 | 7.80 | 6.55 | 52% | 2 | 13 | 15.38% |
| 65.00 | 0.15 | 1.45 | 0.80 | 55% | 26 | 612 | 4.25% |
| 75.00 | 3.00 | 4.90 | 3.95 | 55% | 1 | 347 | 0.29% |
| 40.00 | — | 2.15 | 2.15 | 213% | 0 | 0 | — |
As of Nov 20, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →